Acute Bacterial Skin and Skin Structure Infections Treatment Market Size and Share Outlook: Forecast Trends and Growth Analysis Report (2026-2035)

Company News

In June 2022, Basilea Pharmaceutics attained the permission to apply for the approval of its new antibiotic Ceftobiprole. Basilea will apply for approval on the basis of the results of its TARGET study. This drug, once approved, will be in the acute bacterial skin and skin structure infections treatment market.

In December 2021, Nuzyra, an innovative drug, was approved by China’s NMPA for treating patients with ABSSSIs. It is believed to act on a wide range of pathogens responsible for chronic infections. This will also help in the complete treatment at home, thus saving the patient costs.

In July 2021, the FDA also approved Dalvance, a synthetic glycopeptide which will now help treat ABSSSIs in children. It was earlier only approved for adults.

Introduction of the Acute Bacterial Skin and Skin Structure Infections Treatment Market

Acute bacterial skin and skin structure infections (ABSSSIs) are chronic skin infections with at least one significant lesion size. These infections are generally associated with skin and soft tissues. These acute bacterial skin and skin infections are of two types- complicated and uncomplicated acute bacterial skin and skin infections.

Types of Acute Bacterial Skin and Skin Structure Infections

As the name suggests, complicated infections affect the deeper soft tissue and thus require surgical procedures as a treatment. The causative agents for uncomplicated infections are Streptococcus pyogenes and Staphylococcus aureus. The complicated acute bacterial skin and skin structure infections typically include burns, ulcers, and primary abscesses, while uncomplicated ones include furuncles, superficial abscesses, impetiginous lesions, and cellulitis.

Diagnostic Tools for ABSSSIs 

Standard laboratory tests, radiological examinations, and microbiological examinations are often used to diagnose these infections. The treatment for acute bacterial skin and skin structure infections is speculative and depends on the prevalent signs and symptoms and the type of affected location. A broad spectrum of antibiotics is often prescribed, and the patient is monitored for the entire course duration. Antibiotic therapy must be defined based on the type of the pathogen involved and the varied clinical spectrum of disease.

Out of all the prevailing infections, community-associated methicillin-resistant Staphylococcus aureus accounts for the maximum share in the acute bacterial skin and skin structure infections treatment market. The maximum incidence rate of acute bacterial skin and skin structure infections is witnessed in the United States.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

Acute Bacterial Skin and Skin Structure Infections Treatment Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:

Market Breakup by Infection Type

• Hospital Acquired
• Community Acquired
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Topical
• Others

Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Acute Bacterial Skin and Skin Structure Infections Treatment Market Outlook

The acute bacterial skin and skin structure infections treatment market is driven by the rising number of plaque psoriasis diagnosed cases, which was nearly 125 million in 2021. The prevalence of plaque psoriasis disease is likely to grow at a rate of 21% in the forecast period of 2026-2035 and reach approximately 692 million by 2030.

The growth of the market is also facilitated by the rising incidence of skin and skin structure infections. Skin diseases are among the most prevalent issues experienced by people, affecting about one-third of the global population. Skin diseases account for nearly 1.79% of the worldwide burden of diseases.

According to the 2023 Pubmed statistics, 94 million Europeans complain of skin infections, thus indirectly contributing to a significant share of the market.

The most common causative pathogen for acute bacterial skin and skin structure infections is S. Aureus and streptococci, among other gram-positive bacteria. North America and the Asia Pacific account for the maximum share of the acute bacterial skin and skin structure infections treatment market. Based on gender, acute bacterial skin and skin structure infections are more prevalent in men than women.

The key factors contributing to the acute bacterial skin and skin structure infections treatment market growth include increased prevalence rate, increased awareness among communities, advanced research and development activities and increased clinical trials.

There are several limiting factors which hinder the market expansion. Strict regulatory policies by authorities, termination of the patent license, and antibiotic resistance for various strains hamper the market’s overall development.

The COVID-19 pandemic also worsened the symptoms and condition of acute bacterial skin and skin structure infections in patients and thus, leading to prolonged hospitalisation and treatment. Apart from that, the pandemic also affected the drug and pharmaceuticals’ global supply, thus significantly impacting the treatment market share.

Henceforth, the novel product inventions for treatment by pharmaceutical and biotechnological companies are the key factors driving the market forecast.

North America Accounts for the Maximum Share of the Acute Bacterial Skin and Skin Structure Infections Treatment Market

The United States of America is one of the leading disease treatment markets, accounting for the maximum number of acute skin and skin structure infections globally. In the United States, around 3.3 million patients experienced acute bacterial skin and skin structure infections, leading to an increase in ambulatory care and emergency department visits by 30% and 40%, respectively.  This directly leads to the manifold increase in the acute bacterial skin and skin structure infections treatment market.

Therapeutic Landscape

Acute bacterial skin and skin infections are chronic skin infections affecting the skin and soft tissues. The treatment and management are based on the guidelines published by the World Health Organisation. According to these guidelines, acute bacterial skin and skin infections are divided into two categories: Purulent and Non-Purulent.

Non-purulent acute bacterial skin and skin structure infections include erysipelas and cellulitis, while purulent acute bacterial skin and skin structure infections include abscesses. The different antibiotics are prescribed on the basis and type of the acute bacterial skin and skin structure infections, which are as follows-

• Severe Purulent Infections: Telavancin, Linezolid, Ceftaroline, Tigecycline, and Vancomycin.
• Moderate Purulent Infections: Doxycycline and Trimethoprim-Sulfamethoxazole
• Severe Methicillin-Susceptible S. Aureus Infections: Clindamycin and Cefazolin
• Moderate Methicillin-Susceptible S. Aureus Infections: Cephalexin and Dicloxacillin
• Severe Non-Purulent Infections: Vancomycin plus Piperacillin and Vancomycin plus Tazobactam
• Mild To Moderate Purulent Infections: Clindamycin, Cefazolin, Penicillin, and Ceftriaxone

According to the treatment algorithm, the treatment schedule lasts for about 7-10 days. The discovered antibiotics generally target both gram-positive and gram-negative bacteria. These antibiotic formulations can be administered by both parenteral, oral, and topical routes.

Marketed Drugs Significantly Contributing to the Market Share

The different categories of antibiotics available in the acute bacterial skin and skin structure infections treatment market are Beta Lactams, Cyclic Lipopeptides, Fluoroquinolones, Glycopeptides, Glycylcyclines, Lipoglycopeptides, and Oxazolidinones.

Beta lactams are bactericidal in action and are administered parenterally. At the same time, cyclic lipopeptides are broad-spectrum antibiotics exhibiting concentration dependant bactericidal activity and have reversible side effects on discontinuation of treatment.

Fluoroquinolones are used in treating acute bacterial skin and skin structure infections and consist of quinolones, making them active in an acidic environment and can be administered by both oral and parenteral routes.

Glycopeptides, another class of antibiotics, possess bactericidal action against gram-positive and gram-negative bacteria, while glycylcyclines are a broad-spectrum intravenous class exhibiting action against atypical, anaerobic, gram-positive, gram-negative and few multidrug-resistant pathogens.

Oxazolidinones and lipoglycopeptides act only on gram-positive pathogens and are available in oral and intravenous forms.

Of all the available antibiotics classes, Cephalosporins account for a significant share of the acute bacterial skin and skin structure infections treatment market, followed by Penicillin, Quinolones, Clindamycin, and Tetracyclines.

Patients suffering from acute bacterial skin and skin structure infections opt for hospital visits, ambulatory services, or emergency department visits. The patients can be treated both as inpatients and outpatients. Inpatient care requires the patient to stay in the hospital while outpatient care does not demand any hospital stay.

Alternative Management Options in the Acute Bacterial Skin and Skin Structure Infections Treatment Market

The primary aim of healthcare professionals is to minimise inpatient stays and hospital admissions. Generally, patients with symptoms like lack of aggravation of comorbidities, no signs of sepsis, and low suspicion are manageable as outpatients.

A surgical procedure is another treatment option for acute bacterial skin and skin structure infections. During the surgery, the doctors aim to remove all the foreign agents and drain the infected fluids, thus helping in the eradication ABSSSIs.

The management of acute bacterial skin and skin structure infections is based on two critical objectives: early switch therapy and early discharge.

In early switch therapy, physicians generally aim to switch patients from intravenous to oral route, while in early discharge treatment, the main objective of the physician is to complete the entire treatment after hospital discharge.

Scientists have also discovered some outpatients’ parenteral antimicrobial therapy, which recommends selecting and observing patients and applying antimicrobial treatment in community settings.

Through the acute bacterial skin and skin structure infections treatment market analysis, it was demonstrated that a specific population across the world is more susceptible to these infections than others. This specific population includes elderly people and patients with other co-morbidities like renal impairment, immunosuppression, and cardiovascular diseases. Thus, an increase in this population also drives the growth of the acute bacterial skin and skin structure infections treatment market.

Clinical Trial Landscape

The Food and Drug Administration works endlessly on clinical trials and programs for acute bacterial skin and skin structure infections. According to the new FDA guidelines, the central ideology behind the clinical trials of ABSSSIs drugs and therapy is the application of an active comparator antibacterial drug and medication.

Scientists are working on several clinical trials, which will be accessible in the acute bacterial skin and skin structure treatment market in the coming years.

• Basilea Pharmaceutica Ltd. has recently announced the successful completion of the Phase III study in patients with Staphylococcus aureus bacteremia.
• A new drug possessing the inhibiting action of bacterial hydro folate reductase is also being clinically tested and can soon be used to treat ABSSSIs.
• Another novel drug, non-peptide by chemical nature, seems promising for treating acute bacterial skin and skin structure infections by depolarising bacterial membranes.
• An agent of the pleuromutilin class inhibits bacterial protein synthesis and has successfully passed Phase II clinical trials.
• New class of antibiotics responsible for the bacterial fatty acid biosynthesis acts by blocking the action of the FabI enzyme.
• Novel fluoroquinolones exhibiting bactericidal activity are also evaluated for treating acute bacterial skin and skin structure infections.
• Oxazolidinones are evaluated in the Phase II trials for patients suffering from acute skin and skin structure infections.
• Hybrid rifamycin-quinolone antibiotic, acting on gram-positive bacteria, is also helpful for the ABSSSIs treatment.
• Novel glycopeptide cephalosporin agents also exhibit bactericidal activity and thus can be beneficial for ABSSSIs treatment.
• New drug agents belonging to the triazaacenaphthylene antibacterials were also being studied in Phase II trials. Further evaluation is needed to know the exact role of this novel agent in treating ABSSSIs.
• A bacteriophage encoded peptidoglycan hydrolase is also being found effective for this infection and is still under evaluation.
• A monoclonal antibody possessing potent bactericidal action and is under in vitro studies.

Scientists are also developing new drugs and medications that are antibiotic resistant and have potent action. Several ongoing clinical trials are emerging as a growth driving factor for the acute bacterial skin and skin structure infections treatment market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, putting them through trials to get FDA approvals. The acute bacterial skin and skin structure infections treatment companies included in the market are as follows :

• Paratek Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Melinta Therapeutics
• AbbVie Inc.
• Sandoz International GmbH
• Glenmark Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Aceragen, Inc. (Arrevus, Inc.)
• Accord Healthcare
• Intas Pharmaceuticals
• Fresenius SE & Co. KGaA
• Zydus Lifesciences Limited

Acute Bacterial Skin and Skin Structure Infections Treatment Market Report Snapshots

Acute Bacterial Skin and Skin Structure Infections Treatment Companies